Trade Myriad Genetics

Myriad Genetics Inc. is an American molecular diagnostics company based in Salt Lake City, Utah, United States. Countless proprietary technologies are used that allow doctors and patients to understand the genetic basis of human disease and the role that genes play in the beginning, development and treatment of the disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk of developing the disease later in life (predictive medicine), determine the patient's likelihood of responding to certain pharmacological treatment (precision medicine), assess the patient's risk of disease progression and recurrence of the disease (precision medicine), and measure disease activity. After Mary Claire King discovered that a gene on chromosome 17 was associated with an increased risk of breast cancer, countless tried to patent this gene. These patents were the subject of scrutiny after Myriad became embroiled in a lawsuit over its patent practices, leading to the Landmark Supreme Court decision of the Molecular Pathology Society v. Myriad Genetics, Inc. which ruled that the patents were illegal.